Almost two-thirds of children who receive stem cell transplants are readmitted to the hospital within six months, according to researchers at Dana-Farber/Children’s Hospital Cancer Center in Boston.
Tags: ChildhoodCancer, StemCellTransplant
Dana-Farber researchers detail how low doses of interleukin-2 (IL-2) can alleviate chronic graft-versus-host disease (GVHD) and possibly lead to better treatment for other immune disorders.
Tags: BasicResearch, GraftVersusHost
Celebrating the 60th anniversary of the partnership between the Boston Red Sox and the Jimmy Fund during the home opener, the Jimmy Fund Chorus joined former and current players for their major league debut.
Tags: BostonRedSox, JimmyFund
An irregularity within many neuroblastoma cells may indicate whether the tumor is vulnerable to a new class of anti-cancer drugs known as BET bromodomain inhibitors.
Tags: BasicResearch, ChildhoodCancer
Would you love a chance to win an authentic Boston Red Sox home jersey signed by star outfielder Jacoby Ellsbury? Then "like" Dana-Farber on Facebook.
Tags: BostonRedSox, JimmyFund
Dana-Farber researchers find blood test can provide fuller picture of cancer mutations in gastrointestinal stromal tumors than biopsy.
Tags: BasicResearch
Dana-Farber scientists found that pancreatic cancer cells' growth and spread are fueled by an unusual metabolic pathway that someday might be blocked with targeted drugs to control the deadly cancer.
Tags: BasicResearch, PancreaticCancer, TargetedTherapy
A study by scientists at Dana-Farber Cancer Institute, the Broad Institute, and other research centers, may offer clues to why rates of esophageal adenocarcinomas (EACs) have risen so sharply. The findings, in Nature Genetics, point to an array of abnormal genes and proteins that may be lynchpins of EAC cell growth and therefore serve as targets for new therapies.
Tags: BasicResearch, Genomics, TargetedTherapy
Showing 11-20 of 407 items